Bulls Show Continued Momentum

July 26, 2021 By: Todd Mitchell

The stock market was mostly higher on Friday following the June jobs report with another round of record highs for Tech and the broader market. Specifically, non-farm payrolls rose by 850,000, the sixth-straight monthly gain, versus forecasts for a print of 720,000. The unemployment rate, however, unexpectedly ticked up to 5.9% versus expectations for a dip to 5.6%. The small-caps failed to show...

Continue reading >>

Bitcoin tops $39,000 for the first time in nearly 6 weeks, adding $114 billion to the crypto market

By: Todd Mitchell

...

Continue reading >>

Bulls Push Fresh all-Time Highs

July 25, 2021 By: Todd Mitchell

The stock market was mostly higher on Friday following the June jobs report with another round of record highs for Tech and the broader market. Specifically, non-farm payrolls rose by 850,000, the sixth-straight monthly gain, versus forecasts for a print of 720,000. The unemployment rate, however, unexpectedly ticked up to 5.9% versus expectations for a dip to 5.6%. The small-caps failed to show...

Continue reading >>

Treasury yields climb, 10-year Treasury tops 1.28% ahead of PMI data

July 23, 2021 By: Todd Mitchell

...

Continue reading >>

Bulls Stay Strong Despite Sluggish Session

By: Todd Mitchell

The stock market showed continued strength on Wednesday following upbeat earnings from two blue-chips companies along with a rise in yields. Specifically the 10-year Treasury yield rose to nearly 1.3% after tapping a five-month low on Monday while stabilizing on Tuesday.The drop in rates caught Wall Street by surprise and remains a possible sign of a slowing economy due to the new coronavirus...

Continue reading >>

Extreme Option Profits Chart of Day… Pfizer (PFE)

July 22, 2021 By: Todd Mitchell

Oversold, OCGN is gaining momentum. According to Tip Ranks, “Ocugen has inked a deal with India-based Bharat Biotech for the US rights for the company’s vaccine COVAXIN. And Bharat has now reported positive second interim analysis results from the COVAXIN Phase 3 trials. The vaccine displayed an overall efficacy rate of 78%, with 100% success against severe cases of the disease. COVAXIN...

Continue reading >>
Person with arms crossed

Coming Soon: How $100 A Month Can Grow Into $159,069
— Let Us Show You How!

Join The Index Club
coming Spring 2025



    By registering you are agreeing to our Privacy Policy